Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of HL237 and Tacrolimus in Healthy Men
NCT04633733Phase 1Unknown
- Sponsor
- Hanlim Pharm
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HL237 in rheumatoid arthritis (RA), sponsored by Hanlim Pharm. Primary endpoints: Peak plasma concentration at steady state of HL237 at Day 22, Area under the plasma concentration versus time curve during a dosage interval of HL237 at Day 22 and 2 more. Status: unknown.
02
Drugs
HL237
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04633733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633733.